drugset / Trial / NCT01813487

Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

NCT01813487

Completed 6 enrolled Genexine, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the immunogenicity and efficacy of HBsAg Vaccine in combination with Entecavir in patients who have been treated with HB110E HBV DNA vaccine.

Timeline

Start
2013-02
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HBsAg vaccine Vaccine
Background Entecavir Small molecule